Disruptive Pharma attends CPHI Milan 2026 as formulation scale-up takes focus

PUBT · 1d ago
Disruptive Pharma attends CPHI Milan 2026 as formulation scale-up takes focus
  • Disruptive Pharma attended CPHI Milan 2026 this week, where formulation challenges for complex drug substances were a key industry focus.
  • The company highlighted a shift toward scalable, robust oral drug products, with manufacturing efficiency and limited solvent use as decision drivers.
  • CEO Peter Åsberg said this broader product-development focus is central to the company’s Formulite platform strategy.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Disruptive Pharma AB (publ) published the original content used to generate this news brief on October 09, 2026, and is solely responsible for the information contained therein.